VAFs for validated cases with expansion of nonleukemic hematopoietic clones following induction therapy
| Patient information . | Somatic variants harbored by rising clones . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Age (y) . | Gender . | Karyotype . | Potential driver mutations in AML clone . | Time to relapse (days) . | Gene . | Amino acid change . | COSMIC ID . | VAF at AML diagnosis (%) . | VAF after induction therapy (%) . | VAF at long-term follow-up (%) . | VAF at AML relapse (%) . | VAF after salvage therapy (%) . |
| 192545 | 47 | F | inv(16) | NRAS | 346 | TET2 | Q1828* | COSM87182 | (0.02) | 3.3 (3.8) | 6.4 (6.6) | 5.9 | (5.7) |
| ZNF318 | R1195* | COSM270611 | (0.75) | 29.7 (31.2) | 26.5 (28.5) | 20.9 | (38.0) | ||||||
| 334228 | 63 | M | Normal | FLT3,MYC,NPM1,NRAS | No relapse | CDK13 | C930Y | ND | 39.8 | 30.7 | NA | NA | |
| FLG | R1589C | COSM3385179 | 0.5 | 20.8 | 23.9 | NA | NA | ||||||
| MUC16 | P1955R | ND | ND | 5.9 | NA | NA | |||||||
| 354259 | 61 | M | del(9q) | GATA2,TET2,CEBPA | No relapse | TMEM147 | G105C | ND | 1.1 | 18.9 | NA | NA | |
| TP53 | R280T | COSM10724 | (0.02) | 0.6 (1.2) | 13.2 (18.9) | NA | NA | ||||||
| 746628 | 53 | M | Normal | GATA2,CEBPA | 543 | ACACA | V481I | ND | 3.2 | 13.3 | 9.3 | ND | |
| ASXL1 | S689* | COSM133037 | ND | ND | 5.9 | 3.6 | ND | ||||||
| PTPRK | D1020G | ND | 3.6 | 14.8 | 4.7 | ND | |||||||
| SPATA31E1 | W441* | ND | 2.8 | 11.2 | 22.9 | ND | |||||||
| SPDYC | R158Q | ND | 4.1 | 3 | 1.8 | ND | |||||||
| TP53 | e4-1 | COSM6900 | (0.15) | 3.6 (4.7) | 13.9 (13.7) | 12 | ND | ||||||
| 976838 | 37 | F | Normal | MYC,NPM1,RAD21 | No relapse | DNMT3A | V296M | (0.007) | 0.9 (0.7) | 7.8 (6.4) | NA | NA | |
| KIT | R372G | ND | ND | 2.2 | NA | NA | |||||||
| Patient information . | Somatic variants harbored by rising clones . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient . | Age (y) . | Gender . | Karyotype . | Potential driver mutations in AML clone . | Time to relapse (days) . | Gene . | Amino acid change . | COSMIC ID . | VAF at AML diagnosis (%) . | VAF after induction therapy (%) . | VAF at long-term follow-up (%) . | VAF at AML relapse (%) . | VAF after salvage therapy (%) . |
| 192545 | 47 | F | inv(16) | NRAS | 346 | TET2 | Q1828* | COSM87182 | (0.02) | 3.3 (3.8) | 6.4 (6.6) | 5.9 | (5.7) |
| ZNF318 | R1195* | COSM270611 | (0.75) | 29.7 (31.2) | 26.5 (28.5) | 20.9 | (38.0) | ||||||
| 334228 | 63 | M | Normal | FLT3,MYC,NPM1,NRAS | No relapse | CDK13 | C930Y | ND | 39.8 | 30.7 | NA | NA | |
| FLG | R1589C | COSM3385179 | 0.5 | 20.8 | 23.9 | NA | NA | ||||||
| MUC16 | P1955R | ND | ND | 5.9 | NA | NA | |||||||
| 354259 | 61 | M | del(9q) | GATA2,TET2,CEBPA | No relapse | TMEM147 | G105C | ND | 1.1 | 18.9 | NA | NA | |
| TP53 | R280T | COSM10724 | (0.02) | 0.6 (1.2) | 13.2 (18.9) | NA | NA | ||||||
| 746628 | 53 | M | Normal | GATA2,CEBPA | 543 | ACACA | V481I | ND | 3.2 | 13.3 | 9.3 | ND | |
| ASXL1 | S689* | COSM133037 | ND | ND | 5.9 | 3.6 | ND | ||||||
| PTPRK | D1020G | ND | 3.6 | 14.8 | 4.7 | ND | |||||||
| SPATA31E1 | W441* | ND | 2.8 | 11.2 | 22.9 | ND | |||||||
| SPDYC | R158Q | ND | 4.1 | 3 | 1.8 | ND | |||||||
| TP53 | e4-1 | COSM6900 | (0.15) | 3.6 (4.7) | 13.9 (13.7) | 12 | ND | ||||||
| 976838 | 37 | F | Normal | MYC,NPM1,RAD21 | No relapse | DNMT3A | V296M | (0.007) | 0.9 (0.7) | 7.8 (6.4) | NA | NA | |
| KIT | R372G | ND | ND | 2.2 | NA | NA | |||||||
VAFs based on sequencing (EES ± AmpliSeq) are shown. VAFs based on ddPCR are provided in parentheses.
F, female; M, male; NA, not applicable; ND, not determined.